​Important: Please read instructions thoroughly before starting the late-breakthrough abstract submission.

 

The late-breakthrough abstract submission process is intended for cutting edge, high-level science (both basic and clinical) and is not intended as an extension of the general abstract submission process.

 

The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

​

Main and Sub-Topics

 

Acquired and Critical Care Bleeding

• Perioperative Bleeding

• Coagulopathy of Trauma

• Massive Transfusion Management

• Coagulopathy of Liver and Renal Disease

• Coagulopathy of Other Systemic Diseases

• Antithrombotic Associated Bleeding

Arterial Thromboembolism

• Coronary Artery and Cardiac Disease

• Atrial Fibrillation

• Cerebrovascular Disease

• Peripheral Vascular Disease

• Diagnosis of ATE

• ATE Treatment and Prevention

Coagulation Factors and Co-Factors

• Synthesis and Biochemistry

• Protein Structure and Function

• Non-hemostatic Roles of Coagulation Proteins

Diagnostics, OMICs and Advanced Technologies: This is a broad theme focused on methods. It includes diagnostic laboratory methods, OMICs, novel research methods, experimental models, and advanced technologies including artificial intelligence, machine learning, and mathematical and computational modeling. Please refer to the descriptions below to determine the appropriate subcategory for your abstract.

• Diagnostic Laboratory Methods

  • Abstracts that describe, evaluate, or validate a clinical coagulation or platelet laboratory assay.

• Genomics and Transcriptomics

  • Abstracts in which genomics or transcriptomic approaches are used.

• Proteomics, Metabolomics, and Lipidomics

  • Abstracts in which novel proteomic, metabolomics, or lipidomic approaches are used.

• Novel Research Methods

  • Abstracts that describe, evaluate, or validate novel research methods Abstracts describing, evaluating, or validating novel diagnostic laboratory methods for the clinical coagulation laboratory should be submitted to the “Diagnostic Laboratory Methods” subcategory.

• Artificial Intelligence/Machine Learning

  • Abstracts that use AI or machine learning approaches.

• Mathematical and Computational Models

  • Abstracts that use mathematical or computational modeling approaches.

• Novel Experimental Models in Hemostasis and Thrombosis Disease

  • Abstracts that describe, evaluate, or validate novel experimental in vitro or in vivo models applicable to all areas of hemostasis and thrombosis including platelet and vascular biology.

Fibrinogen, Factor XIII, and Fibrinolysis

• Fibrinogen Structure and Function

• Factor XIII and Other Transglutaminases

• Fibrinolysis and Proteolysis

• Regulation of Fibrinolysis

Inherited Bleeding Disorders and Inhibitors

• Hemophilia

• Von Willebrand Disease

• Rare Factor Deficiencies

• Acquired Factor Deficiencies/Inhibitors

• Vascular Disorders

Modulators of Coagulation and von Willebrand Factor

• Protein C/S Pathway

• Antithrombin and Other Serpins

• TFPI

• Non-hemostatic Roles of Anticoagulant Proteins

• von Willebrand Factor

• ADAMTS13 and Other Proteases

Nurses and Allied Health

• Nurses and Allied Health

Pediatric Hemostasis and Thrombosis

• Neonatal Coagulation Disorders

• Perioperative and Critical Care Coagulation

• Pediatric Bleeding and Thrombosis

• Bleeding and Thrombotic Issues in Adolescence

Platelet Disorders

• Inherited Platelet Disorders

• Immune Thrombocytopenia - ITP, HIT, VITT

• Thrombotic Microangiopathy

• Myeloproliferative Neoplasms and Clonal Disorders

• Acquired Platelet Disorders

Platelets and Megakaryocytes

• Megakaryocyte Biology

• Platelet Biology

• Non-hemostatic Roles of Platelets

• Receptors and Signaling

Vascular Biology, Blood Cells, and Immunothrombosis

• Blood Vessel Structure and Function

• Endothelial Cell Biology

• Inflammation and Thrombosis

• Infection and Immunity

• Extracellular vesicles

• Red Cell Disorders and Coagulation

Venous Thromboembolism

• Deep and Superficial Vein Thrombosis

• Pulmonary Embolism

• Long-term Complications of VTE

• Unusual Site VTE

• Diagnosis of VTE

• VTE Treatment and Prevention

• Thrombophilia

• Cancer-associated Thrombosis

Women's Hemostasis and Thrombosis

• Menstrual Bleeding Disorders

• Hormonal Modulation of Coagulation

• Pregnancy

• Bleeding and Thrombotic Issues in Aging/Postmenopausal Women

 

How to Submit an Abstract

• Delegates, who would like to present their work at the congress, late-breakthrough abstracts will be presented as oral communications, are invited to submit an abstract for consideration by the Scientific Committee.

• ISTH Members and Non-Members are invited to submit abstracts.

• There are no fees to submit an abstract.

• Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

• The submitter will be required to create a new user account in order to submit an abstract. Once logged in, you will be able to submit your abstract. Please note that even if you have submitted in previous years, you will need to create a new user account.

• Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (May 15, 2024, 17:00 Eastern Standard Time (U.S.).

  • You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.

• The submitted/draft abstracts cannot be edited after the submission deadline.

• Only abstracts that have been submitted properly will be considered for the congress.

• Any technical questions regarding the submission website should be sent to abstracts@isth.org.

 

Late-Breakthrough Guidelines

• Late-breakthrough abstracts will not be submitted during the regular abstract submission process. Late-breakthrough abstracts will be submitted following the below timeline:

  • Submission Site Opens: May 8, 2024

  • Submission Site Closes: May 15, 2024

• Late-breakthrough abstracts should highlight novel studies of high impact. Abstracts submitted will be considered if the study is ground breaking and includes novel data. The abstract should not have been previously published or presented in any format. Both basic and clinically focused abstracts can be submitted.

• The late-breakthrough abstract deadline is not intended to be an extension of the regular submission deadline.

• The review and selection process will be highly competitive. No more than five (5) abstracts will be selected to be featured in one (1) Oral Communication Session. If your abstract is not chosen to be included in the Late-Breakthrough Oral Communication Session, it will be rejected. There are no late-breakthrough posters.

 

General Guidelines

• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

• Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.

• Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.

• Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than one (1) topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

• All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

​

ISTH Embargo Policy

You can view the ISTH Embargo Policy here.

​

Preparing an Abstract for Submission
Authors and Co-Authors

• The presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors. The presenting author does not need to be the first author.

• The presenting author of the abstract must be registered for the congress. Abstract will be withdrawn if registration is not completed by June 7, 2024.

• The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived and no virtual presentations will be permitted.

• A maximum of 20 authors is permitted on each abstract, plus one (1) group.

• Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

• Based on current CME guidelines, if the presenting author is employed by industry, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Communication session.

 

Conflict of Interest

• It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting/presenting author of an abstract is required to declare any potential conflicts of interest for the presenting author during abstract submission.

Abstract Body

• For standardization, the acceptable length of the abstract is a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

• Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

• Background

• Aims

• Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

• Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

• Conclusion (or Conclusions): Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

• Other Items for Consideration

  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

  • Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the abstract text.

  • Abbreviations should be defined.

  • If off-label use of drugs was involved in the study, please state this clearly.

Figures and Table

• Figures and tables may be submitted with a maximum file size is 2 MB w. Figures are allowed in the following formats: PNG, GIF, JPG.

• Your abstract may contain two (2) figures or tables; this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

• You will be asked to include a heading for each of your figures/tables to be included as part of the formal published abstract supplement.

 

After Submission
An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts. The presenting author will be notified in early June, at the email address provided during submission, about whether or not their abstract has been accepted.

The reviewers will judge the abstracts according to the following criteria:

• Is the abstract original?

• Does it address an important scientific question?

• Is the abstract clearly written with all salient facts?

• Does the work adhere to ethical guidelines?

• Is there evidence of statistical method if appropriate?

• Are the conclusions justified by the results?

​Please note:

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

• The review and selection process for Late-Breakthrough Abstracts will be highly competitive. No more than four (5) abstracts will be selected and featured in one (1) Oral Communication Session. If your abstract is not chosen to be included in the Late-Breakthrough Oral Communication Session, it will be rejected. Late-Breakthrough Abstract Submission will open on May 8, 2024.

• Late-breakthrough abstracts will be published on the day of the Late-breakthrough Oral Communication session. Late-breakthrough titles will be made available prior to the congress.

• All accepted Late-breakthrough abstracts will be published as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH) and will be made available on the ISTH Congress website after the congress.

​​

Withdrawal Policy
If authors wish to withdraw their abstracts from presentation or publication they are requested to notify ISTH via e-mail to abstracts@isth.org before June 7, 2024. Withdrawn abstracts will not be presented nor will these be published.

 

Technical Requirements
The online abstract submission system works best with Google Chrome and Mozilla Firefox. Cookies and JavaScript need to be enabled.

 

Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed.

To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  

In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.